Antisense oligonucleotides complementary to the primary transcript of the human c-fes protooncogene
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 19, 1999
Grant Date -
N/A
app pub date -
May 20, 1997
filing date -
May 20, 1996
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The following description sets forth antisense (AS) oligonucleotides (ODNs) complementary to the primary transcript of the human c-fes protooncogene and their use to inactivate said transcript. All-trans retinoic acid (ATRA) is reported to be used as a differentiation inducer on cells pretreated with said AS-ODNs to induce apoptosis of leukemic blast cells.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully